NSE: STAR | BSE: 532531

Strong Performer, Under Radar

Download real time

1020.00 -11.60 (-1.12%)

32.70% Gain from 52W Low

87,155 NSE+BSE Volume

NSE 24 Jul, 2026 3:31 PM (IST)

9,401.6

Market Cap

Above industry Median

Beta 1Year

Very Low volatility

Dividend

Strides Pharma has an upcoming dividend of ₹5.000 per share due on 31 Jul 2026 See details

Strides Pharma Science Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for STAR, BSE:532531 Strides Pharma Science Ltd.

Strides Pharma Science Ltd.

18 Aug 2017

1020.00

-1.12%

Result Update - Strides Shasun

Buy: Strides Pharma Science Ltd.

Target

Axis Direct

Q1 revenue growth (10% YoY) was in line, but EBITDA declined 34% YoY (37% below our expectations) on lower gross margin of 50.2% (down 260 bps YoY). Gross margin declined due to (1) price erosion in key partnership products in US; delay in its key approvals

Number of FII/FPI investors increased from 248 to 262 in Jun 2026 qtr.

Strides Pharma Science Ltd.

14 Aug 2017

1020.00

-1.12%

Strides Shasun Ltd Q1FY18 results comment

Results Update: Strides Pharma Science Ltd.

HDFC Securities

Revenue decreased by 5.25% to Rs. 841.77 Cr in Q1FY18 when compared to the previous quarter. Revenue decreased by 5.25% to Rs. 841.77 Cr in Q1FY18 when compared to the previous quarter.

Number of FII/FPI investors increased from 248 to 262 in Jun 2026 qtr.

Strides Pharma Science Ltd.

29 May 2017

1020.00

-1.12%

Result Update:Strides Shasun

Buy: Strides Pharma Science Ltd.

Axis Direct

Strides reported Q4'17 EBITDA of Rs 1.56bn, 28% below our expectations, hit by challenging environment across key markets. EBITDA including other income was Rs 2.1 bn, which is ~95% of H2'17 EBITDA guidance.

Promoters pledged 10.83% of shares in last quarter. Total pledge stands at 38.10% of promoter holdings

Strides Pharma Science Ltd.

26 May 2017

1020.00

-1.12%

Strides Shasun Ltd Q4FY17 results comment

Results Update: Strides Pharma Science Ltd.

HDFC Securities

Revenue fell by 8.86% to Rs. 522.8 Cr in Q4FY17 when compared to the previous quarter.

Strides Pharma has gained 28.10% in the last 6 Months

Strides Pharma Science Ltd.

06 Feb 2017

1020.00

-1.12%

Strides Shasun Ltd Q3FY17 results comment

Results Update: Strides Pharma Science Ltd.

HDFC Securities

Revenue decreased by 4.98% to Rs. 876.29 Cr in Q3FY17 when compared to the previous quarter. On the other hand, it grew by 5.11% when compared with Q3FY16.

Promoters pledged 10.83% of shares in last quarter. Total pledge stands at 38.10% of promoter holdings

Strides Pharma Science Ltd.

17 May 2016

1020.00

-1.12%

Strides Shasun Limited

Strides Pharma Science Ltd.

ICICI Securities Limited

Q4FY16 consolidated revenues grew 43% YoY to | 1002 crore due to 115% growth in regulated markets (34% of revenues) and 102% growth in the institutional business (19% of revenues). On the other hand, PSAI...

Strides Pharma has gained 28.10% in the last 6 Months

Strides Pharma Science Ltd.

27 Oct 2015

1020.00

-1.12%

Strides Arcolab - 2QFY16 Result Update

Buy: Strides Pharma Science Ltd.

Reliance Securities

Margins in line, higher other income beats profits Strides' 2QFY16 result was in-line on the operating front at 13.1%; however, higher other income led to 20% beat in profitability. The regulated market (including 1 month of Arrow sales) remained the pioneer of growth led by ramp up in new products. Management has guided for sales of Rs18-20bn and EBITDA of Rs3.53.8bn in 2HFY16E. We remain optimistic on company's business prospects in India, Africa and the US. Besides, its merger with Shasun and integration of Arrow Pharma will help create significant value over medium term, as operational synergies play out. Focus on increasing profitability and reduction in debt remains...

Number of FII/FPI investors increased from 248 to 262 in Jun 2026 qtr.

Is Strides Pharma Science Ltd. worth buying?

494 Votes:

Buy 78.95%

Sell 11.74%

Hold 9.31%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf